Multidrug-Resistant Tuberculosis (MDR TB)
and Extensively-Drug Resistant (XDR) TB

Return to XDR/MDR Webinar

Text for PowerPoint Slides

Welcome and Overview

Slide 1: Multidrug-Resistant Tuberculosis (MDR TB) and Extensively-Drug Resistant (XDR) TB: A Web-Based Seminar

Slide 2: Welcome and Introduction

Slide 3: Collaboration

Slide 4: TB Regional Training and Medical Consultation Centers

Slide 5: Learning Objectives

Slide 6: Agenda

Slide 7: Continuing Education Credits

Slide 8: Continuing Education Disclaimer Statement

Return to Top

MDR/XDR TB: Global Problem, Domestic Implications

Slide 9: MDR/XDR TB: Global Problem, Domestic Implications
L. Masae Kawamura, MD

Slide 10: Timebomb

Slide 11: Definitions

Slide 12: Global Drug-Resistant TB: How Bad Is It?

Slide 13: 2006 Global Distribution of MDR TB among New Cases

Slide 14: WHO Map – Countries with XDR TB Confirmed Cases to Date

Slide 15: Global Drug-Resistant TB: MDR/XDR TB Fuel

Slide 16: Primary MDR TB, United States, 1993–2005

Slide 17: Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2005

Slide 18: XDR TB in the US: 1993-2007*

Slide 19: XDR TB Cases in the United States (Initial DST), 1993–2007*

Slide 20: Primary U.S. XDR TB Counted Cases as Defined on Initial DST by Year, 1993–2007*

Slide 21: XDR TB Pie Chart and Table

Slide 22: Outcomes of XDR TB Counted Cases Defined on Initial DST, 1993–2007*

Slide 23: Death of XDR TB Counted Cases Defined on Initial DST, 1993–2007

Slide 24: Have germs, will travel…

Return to Top

Laboratory Aspects of Drug-Resistant Tuberculosis

Slide 25: Laboratory Aspects of Drug-Resistant Tuberculosis
Thomas M. Shinnick, Ph.D.

Slide 26: Spontaneous mutations develop as bacilli proliferate to >10⁸

Slide 27: Drug-resistant mutants

Slide 28: Drug-resistant mutants (cont.)

Slide 29: Role of the Laboratory

Slide 30: Drug Susceptibility Testing

Slide 31: Agar Proportion Method

Slide 32: Critical Concentration

Slide 33: Critical Concentrations

Slide 34: Critical Concentration

Slide 35: Reasons for Discordant DST Results

Slide 36: Problem Drugs

Slide 37: Difficult Strains

Slide 38: Summary

Return to Top

Averting Disaster: Principles in Preventing and Managing Drug Resistant TB

Slide 39: Averting Disaster: Principles in Preventing and Managing Drug-Resistant TB

Slide 40: Patient History

Slide 41: Treatment History

Slide 42: Treatment History (cont.)

Slide 43: Treatment History (cont.)

Slide 44: Drug-O-Gram: Initial Regimens

Slide 45: Poor Patient Outcome with Failure to Follow Principles of Care

Slide 46: Ten Years Later…Patient History (cont.)

Slide 47: Retreatment Regimen

Slide 48: Drug Susceptibility Testing from Commercial Lab

Slide 49: Retreatment Course

Slide 50: Treatment Failure

Slide 51: Discussion of Retreatment: Appropriate Management Decisions

Slide 52: Approach to Treatment of MDR TB: Errors in Management

Slide 53: Approach to Treatment of MDR TB: Errors in Management (cont.)

Slide 54: Building a Treatment Regimen

Slide 55: Building a Treatment Regimen (cont)

Slide 56: Building a Treatment Regimen (cont)

Slide 57: Retreatment Course Continued

Slide 58: Drug Susceptibility Test Results from National Reference Lab

Slide 59: Retreatment Course

Slide 60: Drug-O-Gram: Retreatment

Slide 61: Approach to Treatment of MDR TB: Errors in Management

Slide 62: Principles for Managing MDR TB

Slide 63: Principles for Managing MDR TB (cont.)

Return to Top

Management of Contacts to Cases of MDR/XDR

Slide 64: Management of Contacts to Cases of MDR and XDR

Slide 65: Transmission of Tuberculosis

Slide 66: Challenges to an Evidence-Based Approach to Management of Contacts to MDR and XDR TB

Slide 67: Are drug-resistant strains as transmissible as drug-susceptible strains?

Slide 68: Are drug-resistant strains likely to progress to active disease once infection is established?

Slide 69: Secondary Case Rate Ratio (SR) of Drug-Resistant (DR) Strains, by (HIV) Serostatus and Place of Birth

Slide 70: Are drug-resistant strains likely to progress to active disease once infection is established?

Slide 71: Conflicting Data

Slide 72: Are drug-resistant strains likely to progress to active disease once infection is established?

Slide 73: Are drug-resistant strains as likely to progress to active disease?

Slide 74: Are all MDR and XDR strains equally virulent?

Slide 75: Should we treat or follow contacts to MDR/XDR?

Slide 76: Practical Points in Treating MDR/XDR Contacts

Slide 77: Treatment Outcomes of MDR Contacts

Slide 78: Treatment Outcomes of MDR Contacts (cont.)

Slide 79: Summary

Return to Top

Lessons and Resources

Slide 80: MDR and XDR TB: Lessons & Resources

Slide 81: Lessons from US Traveler with XDR/MDR TB

Slide 82: Lessons from US Traveler with XDR/MDR TB (cont.)

Slide 83: Consultation

Slide 84: Regional Training and Medical Consultation Centers

Slide 85: Regional Training and Medical Consultation Centers

Slide 86: RTMCC Training

Slide 87: RTMCC Educational Products & Resources for XDR/MDR

Slide 88: Additional XDR and MDR TB Educational Resources

Slide 89: CDC’s Extensively Drug-Resistant Tuberculosis (XDR TB) Webpage

Slide 90: CDC’s Extensively Drug-Resistant Tuberculosis (XDR TB) Webpage

Slide 91: CDC’s XDR TB Webpage (cont.)

Slide 92: Acknowledgements

Slide 93: CDC and Regional Training and Medical Consultation Centers

Slide 94: Panel Discussion

Return to Top

 
Back to Top of Page

If you would like to order any of the DTBE publications please visit the online order form.

You will need Adobe Acrobat™ Reader v5.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: cdcinfo@cdc.gov

Home | Site Map | Contact Us
Accessibility | Privacy Policy Notice | FOIA | USA.gov
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: CDCINFO@cdc.gov